Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01305
|
|||||
Drug Name |
Bisantrene
|
|||||
Synonyms |
39C34M111K; 78186-34-2; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazon); 9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-; BISANTRENE HYDROCHLORIDE; BRN 0966309; Bisantrene; Bisantrene [INN]; Bisantreno; Bisantreno [INN-Spanish]; Bisantrenum; Bisantrenum [INN-Latin]; CHEMBL25336; CL 216942; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazono)methyl]-9-anthryl]methyleneamino]-4,5-dihydro-1H-imidazol-2-amine; NSC 337766; UNII-39C34M111K
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Acute myelogenous leukemia [ICD11: 2B33.1] | Phase 2 | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C22H22N8
|
|||||
Canonical SMILES |
C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5
|
|||||
InChI |
InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)/b27-13+,28-14+
|
|||||
InChIKey |
NJSMWLQOCQIOPE-OCHFTUDZSA-N
|
|||||
CAS Number |
CAS 78186-34-2
|
|||||
Pharmaceutical Properties | Molecular Weight | 398.5 | Topological Polar Surface Area | 97.6 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 6 | |||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 4 | |||
XLogP |
1.9
|
|||||
PubChem CID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
References | ||||||
1 | ClinicalTrials.gov (NCT03820908) Bisantrene for Relapsed /Refractory AML | |||||
2 | Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9. | |||||
3 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.